AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11157881 — intervention group
Group type: EXPERIMENTAL
Intervention: Manifest refraction
Number of subjects: 29
Study 11157881 — intervention group
Group type: COMPARATOR
Intervention: Autorefraction
Number of subjects: 29
Study 11015795 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine (n = 595 in 1997-1998; n = 587 in 1998-1999)
Number of subjects: 2375
Study 11015795 — intervention group
Group type: COMPARATOR
Intervention: Sterile saline injection (placebo; n = 589 in 1997-1998; n = 604 in 1998-1999)
Number of subjects: 2375
Study 8783304 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthetic cream
Number of subjects: 28
Study 8783304 — intervention group
Group type: COMPARATOR
Intervention: Control cream
Number of subjects: 28
Study 8783304 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric contraction at 22% MVC
Number of subjects: 28
Study 1617901 — intervention group
Group type: EXPERIMENTAL
Intervention: True mud packs (Group 1)
Number of subjects: 28
Study 1617901 — intervention group
Group type: COMPARATOR
Intervention: Washed out and less concentrated mud packs (Group 2)
Number of subjects: 28
Study 6547072 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy (Adriamycin 25 mg/m2, cyclophosphamide 700 mg/m2, vincristine 1.5 mg/m2, arabinosylcytosine 100 mg/m2, methotrexate 10 mg/m2, prednisone 60 mg/m2) and radiotherapy (2000 rad)
Number of subjects: 73
Study 6547072 — intervention group
Group type: COMPARATOR
Intervention: Combination chemotherapy and radiotherapy
Number of subjects: 73
Study 6547072 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudomonas vaccine
Number of subjects: 73
Study 29982844 — intervention group
Group type: EXPERIMENTAL
Intervention: Full range of motion (FULL) training
Number of subjects: 19
Study 29982844 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial range of motion (PART) training
Number of subjects: 19
Study 29982844 — intervention group
Group type: COMPARATOR
Intervention: Control group (Control)
Number of subjects: 19
Study 26791569 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerised interpretation of the CTG with decision-support
Number of subjects: 46000
Study 26791569 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care without decision-support)
Number of subjects: 46000
Study 23124275 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist self-report measure of evidence-based practices (ITT-ABP)
Number of subjects: 71
Study 22342006 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneal collagen crosslinking (CXL)
Number of subjects: 76
Study 20332354 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM)
Number of subjects: 2
Study 17679725 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 8650
Study 17679725 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 8650
Study 17679725 — intervention group
Group type: EXPERIMENTAL
Intervention: Centrally assessed ER and PgR
Number of subjects: 8650
Study 17679725 — intervention group
Group type: EXPERIMENTAL
Intervention: Centrally assessed hormone receptor status
Number of subjects: 8650
Study 15910745 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of novel truncated isoforms of SAA4 using MALDI-TOF MS
Number of subjects: 0
Study 15910745 — intervention group
Group type: EXPERIMENTAL
Intervention: Patterns of isoform distribution
Number of subjects: 0
Study 11903513 — intervention group
Group type: EXPERIMENTAL
Intervention: Piribedil (3 mg)
Number of subjects: 12
Study 11903513 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9874055 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal of antihypertensive medication
Number of subjects: 975
Study 9874055 — intervention group
Group type: COMPARATOR
Intervention: Nonpharmacologic therapy (weight loss and/or sodium reduction)
Number of subjects: 975
Study 9139386 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole (400 mg twice daily for 5 days)
Number of subjects: 35
Study 9139386 — intervention group
Group type: COMPARATOR
Intervention: Thiabendazole (1 g twice daily for 5 days)
Number of subjects: 35
Study 2229463 — intervention group
Group type: COMPARATOR
Intervention: Flurazepam 30 mg
Number of subjects: 99
Study 2229463 — intervention group
Group type: COMPARATOR
Intervention: Flurazepam 15 mg
Number of subjects: 99
Study 2229463 — intervention group
Group type: COMPARATOR
Intervention: Midazolam 15 mg
Number of subjects: 99
Study 2229463 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 31621538 — intervention group
Group type: EXPERIMENTAL
Intervention: Friend PSA
Number of subjects: 188
Study 31621538 — intervention group
Group type: EXPERIMENTAL
Intervention: Labeling PSA
Number of subjects: 188
Study 29723341 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led medication counseling session at discharge and telephone follow-up three and 15 days after discharge.
Number of subjects: 104
Study 29723341 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pharmacist-led counseling).
Number of subjects: 104
Study 29723341 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led medication counseling session at discharge.
Number of subjects: 104
Study 26548341 — intervention group
Group type: EXPERIMENTAL
Intervention: Home walking exercise (8 weeks of aerobic conditioning: 60 minutes/day, 5 days/week; followed by 16 weeks of aerobic maintenance: 150 minutes/week, 30 minutes/session at 60-80% of heart rate reserve)
Number of subjects: 84
Study 26548341 — intervention group
Group type: EXPERIMENTAL
Intervention: Home walking exercise
Number of subjects: 84
Study 24563084 — intervention group
Group type: EXPERIMENTAL
Intervention: LIS (nutraceutical product containing Garcinia cambogia, l-carnitine, and Ascophyllum nodosum)
Number of subjects: 28
Study 24563084 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 28
Study 22196835 — intervention group
Group type: EXPERIMENTAL
Intervention: theory‐based education plus MEMS feedback
Number of subjects: 82
Study 22196835 — intervention group
Group type: EXPERIMENTAL
Intervention: theory‐based education only
Number of subjects: 82
Study 22196835 — intervention group
Group type: COMPARATOR
Intervention: usual care (control)
Number of subjects: 82
Study 20662896 — intervention group
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL) 800 mg once daily
Number of subjects: 314
Study 17717534 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucromalt (50 g)
Number of subjects: 40
Study 17717534 — intervention group
Group type: COMPARATOR
Intervention: HFCS (50 g)
Number of subjects: 40
Study 17717534 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucromalt (80 g)
Number of subjects: 40
Study 17717534 — intervention group
Group type: COMPARATOR
Intervention: HFCS (80 g)
Number of subjects: 40
Study 17717534 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose/glucose blend (56 g) + inulin (24 g)
Number of subjects: 40
Study 15765446 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsule endoscopy
Number of subjects: 30
Study 12441039 — intervention group
Group type: EXPERIMENTAL
Intervention: Various therapies for inflammatory bowel disease (IBD)
Number of subjects: 0
Study 12441039 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical activity indices
Number of subjects: 0
Study 12441039 — intervention group
Group type: EXPERIMENTAL
Intervention: New activity indices
Number of subjects: 0
Study 10483964 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral verapamil (240 mg/day) initiated three days before cardioversion and continued during follow-up (group II)
Number of subjects: 107
Study 10483964 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral verapamil (240 mg/day) administered three days before and continued only for three days after cardioversion (group III)
Number of subjects: 107
Study 10483964 — intervention group
Group type: COMPARATOR
Intervention: Oral propafenone (900 mg/day) only (group I)
Number of subjects: 107
Study 10483964 — intervention group
Group type: COMPARATOR
Intervention: Comparison of AF free survival curves between group I (propafenone only) and group II (verapamil + propafenone)
Number of subjects: 107
Study 10483964 — intervention group
Group type: COMPARATOR
Intervention: Comparison of AF free survival curves between group I (propafenone only) and group III (verapamil before and after cardioversion)
Number of subjects: 107
Study 8758387 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C (MMC) 0.4 mg/ml used in trabeculectomy
Number of subjects: 30
Study 8758387 — intervention group
Group type: COMPARATOR
Intervention: Control group (no MMC)
Number of subjects: 30
Study 1877445 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill exercise test (positive)
Number of subjects: 838
Study 1877445 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill exercise test (negative)
Number of subjects: 838
Study 1877445 — intervention group
Group type: COMPARATOR
Intervention: Positive or negative test result (with or without angina)
Number of subjects: 838
Study 7045755 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin plus gentamicin
Number of subjects: 305
Study 7045755 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefamandole (2, 1, and 1 g)
Number of subjects: 305
Study 7045755 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefamandole (2, 2, and 2 g)
Number of subjects: 305
Study 30328241 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based program (MBP) for 8 weeks
Number of subjects: 99
Study 30328241 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 99
Study 28537437 — intervention group
Group type: EXPERIMENTAL
Intervention: In-home closed-loop technology for four nights
Number of subjects: 16
Study 26427106 — intervention group
Group type: EXPERIMENTAL
Intervention: Zhenjingdingzhi decoction
Number of subjects: 100
Study 26427106 — intervention group
Group type: COMPARATOR
Intervention: Suanzaoren decoction
Number of subjects: 100
Study 24248424 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate characteristics monitoring
Number of subjects: 1489
Study 23503089 — intervention group
Group type: COMPARATOR
Intervention: WB-GTH-Basic intervention
Number of subjects: 247
Study 23503089 — intervention group
Group type: COMPARATOR
Intervention: WB-GTH-Enhanced intervention
Number of subjects: 247
Study 19746201 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradetrusor injections of botulinum toxin‐A (BTX‐A)
Number of subjects: 100
Study 17309380 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapas Acupressure Technique (TAT)
Number of subjects: 88
Study 17309380 — intervention group
Group type: COMPARATOR
Intervention: Self-directed support (SDS)
Number of subjects: 88
Study 17309380 — intervention group
Group type: EXPERIMENTAL
Intervention: Qigong (QI)
Number of subjects: 88
Study 15140336 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 70 mg once weekly
Number of subjects: 449
Study 15140336 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 449
Study 11124714 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine
Number of subjects: 0
Study 11124714 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibutilide and Dofetilide
Number of subjects: 0
Study 11124714 — intervention group
Group type: COMPARATOR
Intervention: Electrical cardioversion
Number of subjects: 0
Study 11124714 — intervention group
Group type: EXPERIMENTAL
Intervention: Procainamide
Number of subjects: 0
Study 11124714 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 0
Study 11124714 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine and Bretylium
Number of subjects: 0
Study 11124714 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenergic blockade
Number of subjects: 0
Study 9581713 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenting of the infarct-related artery (IRA)
Number of subjects: 150
Study 9581713 — intervention group
Group type: COMPARATOR
Intervention: Optimal primary angioplasty (PTCA)
Number of subjects: 150
Study 9581713 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenting of the IRA
Number of subjects: 150
Study 7520188 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (140 mg primed in ECC pump, continuous IV perfusion at 70 mg/h)
Number of subjects: 110
Study 7520188 — intervention group
Group type: COMPARATOR
Intervention: Control group (no aprotinin)
Number of subjects: 110
Study 2645550 — intervention group
Group type: EXPERIMENTAL
Intervention: Apraclonidine 1.0%
Number of subjects: 18
Study 2645550 — intervention group
Group type: COMPARATOR
Intervention: Dipivefrin 0.1%
Number of subjects: 18
Study 2645550 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 29360701 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracorporeal anastomosis
Number of subjects: 60
Study 29360701 — intervention group
Group type: COMPARATOR
Intervention: Extracorporeal anastomosis
Number of subjects: 60
Study 26498428 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant-current (CC) stimulation
Number of subjects: 19
Study 26498428 — intervention group
Group type: COMPARATOR
Intervention: Constant-voltage (CV) stimulation
Number of subjects: 19
Study 26498428 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed implants (CC after CV replacement)
Number of subjects: 19
Study 26498428 — intervention group
Group type: EXPERIMENTAL
Intervention: IPG replacement procedure
Number of subjects: 19
Study 26335133 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-assessment of vision
Number of subjects: 93
Study 26335133 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-assessment of hearing
Number of subjects: 93
Study 24352414 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized working memory training (25-day training program at school)
Number of subjects: 67
Study 24352414 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (control group)
Number of subjects: 67
Study 20934573 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 0
Study 18831859 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine, 10 mg, once daily
Number of subjects: 835
Study 18831859 — intervention group
Group type: COMPARATOR
Intervention: Fexofenadine, 60 mg, twice daily
Number of subjects: 835
Study 18831859 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 835
Study 16115151 — intervention group
Group type: EXPERIMENTAL
Intervention: TRAP Vascular Filtration System (VFS)
Number of subjects: 467
Study 16115151 — intervention group
Group type: COMPARATOR
Intervention: Control (no TRAP device)
Number of subjects: 467
Study 12146000 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane 0.5-50 mg/day after breakfast for 7 days
Number of subjects: 32
Study 10586564 — intervention group
Group type: EXPERIMENTAL
Intervention: Portex Profile Soft‐Seal Cuff (PSSC)
Number of subjects: 30
Study 10586564 — intervention group
Group type: EXPERIMENTAL
Intervention: Portex Profile Cuff (PC)
Number of subjects: 30
Study 10586564 — intervention group
Group type: COMPARATOR
Intervention: Mallincrodt Lo‐Contour (LC)
Number of subjects: 30
Study 7768247 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (5 mg once daily)
Number of subjects: 320
Study 7768247 — intervention group
Group type: COMPARATOR
Intervention: Slow release nifedipine (20 mg twice daily)
Number of subjects: 320
Study 2375291 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemented preterm human milk with bovine milk protein, calcium, phosphorus, and sodium
Number of subjects: 0
Study 2375291 — intervention group
Group type: COMPARATOR
Intervention: Unsupplemented preterm human milk
Number of subjects: 0
Study 7023173 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE2 tablets (ProstinR)
Number of subjects: 471
Study 7023173 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin intravenously
Number of subjects: 471
Study 7023173 — intervention group
Group type: COMPARATOR
Intervention: Primary amniotomy
Number of subjects: 471
Study 7023173 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE2
Number of subjects: 471
Study 7023173 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 471
Study 7023173 — intervention group
Group type: COMPARATOR
Intervention: PGE2 and Oxytocin
Number of subjects: 471
Study 30919006 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline 100 mg
Number of subjects: 48
Study 30919006 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline 200 mg
Number of subjects: 48
Study 30919006 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 30919006 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline
Number of subjects: 48
Study 28662834 — intervention group
Group type: EXPERIMENTAL
Intervention: App with remote support
Number of subjects: 80
Study 28662834 — intervention group
Group type: COMPARATOR
Intervention: Paper handouts
Number of subjects: 80
Study 25872126 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based model of care
Number of subjects: 65
Study 25872126 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 65
Study 24093711 — intervention group
Group type: EXPERIMENTAL
Intervention: Local tenoxicam injection (1 mL of tenoxicam 20 mg/2 mL and 1 mL of 2% lidocaine)
Number of subjects: 61
Study 24093711 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid injection (1 mL containing 40 mg of methylprednisolone acetate and 1 mL of 2% lidocaine)
Number of subjects: 61
Study 24093711 — intervention group
Group type: COMPARATOR
Intervention: Comparison between tenoxicam and corticosteroid groups
Number of subjects: 61
Study 21628305 — intervention group
Group type: EXPERIMENTAL
Intervention: Anidulafungin
Number of subjects: 0
Study 21628305 — intervention group
Group type: COMPARATOR
Intervention: Fluconazole
Number of subjects: 0
Study 19462320 — intervention group
Group type: EXPERIMENTAL
Intervention: Mare's milk (250 ml daily for 16 weeks)
Number of subjects: 23
Study 19462320 — intervention group
Group type: COMPARATOR
Intervention: Placebo (250 ml daily for 16 weeks)
Number of subjects: 23
Study 17920504 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (650 mg)
Number of subjects: 33
Study 17920504 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen (400 mg)
Number of subjects: 33
Study 15257848 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart disease prevention program (12 weekly sessions on lifestyle change and goal setting)
Number of subjects: 76
Study 15257848 — intervention group
Group type: COMPARATOR
Intervention: Control group (32 participants)
Number of subjects: 76
Study 12479189 — intervention group
Group type: EXPERIMENTAL
Intervention: M6G
Number of subjects: 144
Study 12479189 — intervention group
Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 144
Study 9526208 — intervention group
Group type: EXPERIMENTAL
Intervention: Suction drainage
Number of subjects: 48
Study 9526208 — intervention group
Group type: COMPARATOR
Intervention: No suction drainage
Number of subjects: 48
Study 8031164 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: 400 mg of UFT orally for 7 days preoperatively, bolus 20 mg of MMC on the day of operation, bolus 10 mg of MMC the day after operation, followed by 800 mg of FT intravenously for 2 weeks and daily oral administration of 400 mg of UFT thereafter
Number of subjects: 35
Study 8031164 — intervention group
Group type: COMPARATOR
Intervention: Group B: Bolus 20 mg of MMC on the day of surgery, bolus 10 mg the day after surgery, and 400 mg of UFT orally daily from 2 weeks after surgery
Number of subjects: 35
Study 8031164 — intervention group
Group type: COMPARATOR
Intervention: Group C: 400 mg of UFT alone daily orally from 2 weeks after surgery
Number of subjects: 35
Study 3136064 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg disopyramide
Number of subjects: 23
Study 3136064 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg tocainide
Number of subjects: 23
Study 3136064 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg flecainide
Number of subjects: 23
Study 30132751 — intervention group
Group type: EXPERIMENTAL
Intervention: Revascularization
Number of subjects: 500
Study 30132751 — intervention group
Group type: COMPARATOR
Intervention: Medical management alone
Number of subjects: 500
Study 28888094 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (100‐kVp and iodixanol 270 mg/mL with ASIR 40%)
Number of subjects: 136
Study 28888094 — intervention group
Group type: COMPARATOR
Intervention: Group A (120‐kVp and iopromide 370 mg/mL with FBP)
Number of subjects: 136
Study 26180221 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 127
Study 23111827 — intervention group
Group type: EXPERIMENTAL
Intervention: PCL-preserving group (42 knees)
Number of subjects: 90
Study 23111827 — intervention group
Group type: COMPARATOR
Intervention: PCL-sacrificing group (44 knees)
Number of subjects: 90
Study 21476961 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL-C target of < 100 mg/dl
Number of subjects: 1123
Study 21476961 — intervention group
Group type: COMPARATOR
Intervention: LDL-C target of < 130 mg/dl
Number of subjects: 1123
Study 19593175 — intervention group
Group type: EXPERIMENTAL
Intervention: OFC (olanzapine/fluoxetine combination)
Number of subjects: 114
Study 19593175 — intervention group
Group type: COMPARATOR
Intervention: OLZ (olanzapine monotherapy)
Number of subjects: 114
Study 16551905 — intervention group
Group type: EXPERIMENTAL
Intervention: 66% N2O with isoflurane
Number of subjects: 90
Study 16551905 — intervention group
Group type: EXPERIMENTAL
Intervention: 66% N2O with sevoflurane
Number of subjects: 90
Study 16551905 — intervention group
Group type: COMPARATOR
Intervention: isoflurane alone
Number of subjects: 90
Study 16551905 — intervention group
Group type: COMPARATOR
Intervention: sevoflurane alone
Number of subjects: 90
Study 16551905 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 microg/kg IV fentanyl
Number of subjects: 90
Study 12919456 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional education and implementation of a nutritional programme
Number of subjects: 176
Study 10862642 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flux dialysis
Number of subjects: 48
Study 10862642 — intervention group
Group type: COMPARATOR
Intervention: Low-flux dialysis
Number of subjects: 48
Study 9112219 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-2.5 x 10(6) CD34+ cells/kg
Number of subjects: 45
Study 9112219 — intervention group
Group type: EXPERIMENTAL
Intervention: greater than 2.5 x 10(6) CD34+ cells/kg
Number of subjects: 45
Study 9112219 — intervention group
Group type: EXPERIMENTAL
Intervention: Threshold dose of 1 x 10(6) CD34+ cells/kg
Number of subjects: 45